TickerTalks
Browse all tickers →
TickerTalks›$NRXP
NRNRXP

NRx Pharmaceuticals, Inc.

$NRXP·$72M·Biotechnology·Healthcare
$4.24-4.9%YTD+54.2%1Y+40.9%
Mentions · last 7 days
2026-07-09: 2 posts2026-07-10: 0 posts2026-07-11: 1 posts2026-07-12: 2 posts2026-07-13: 1 posts2026-07-14: 5 posts2026-07-15: 1 posts12+22%
Price updated 5h ago·X counts updated 1d ago
NRNRXP
$NRXPNRx Pharmaceuticals, Inc.
$4.24-4.93%12 posts+22%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $NRXP, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-07-16

The move is getting stronger, with heavier trading behind it.

Depression and PTSD micro-cap running an FDA-cleared TMS rollout through HOPE Therapeutics while a Kadima contract dispute plays out in court.

NRx is a specialty biotech whose current commercial vector runs through subsidiary HOPE Therapeutics — a clinical-services build focused on transcranial magnetic stimulation (TMS) for treatment-resistant depression, layered with the D-cycloserine augmentation programme (NRX-101) and adjacent digital-mental-health partnerships.

  • Q1 EPS printed at negative $0.04 versus the negative $0.05 estimate — a 20% beat — after Q4's 311% surprise, reflecting the shift into revenue-generating HOPE Therapeutics services rather than pure R&D burn.
  • Analysts model calendar-26 revenue of $13.9M loss $0.37 EPS, then a step-change to $166M revenue and positive $0.35 EPS in 2027 — the forward jump is the entire story and requires HOPE Therapeutics clinics to scale on schedule.
  • The Kadima Neuropsychiatry Institute filed suit against NRx on 24 June alleging breach of contract on the acquisition — a live litigation overhang that management has responded to publicly.
  • The FDA granted an expanded-access protocol for NRX-101 in augmentation of TMS on 22 June; HOPE Therapeutics treated the first patient using Zeta Surgical's FDA-cleared Zeta TMS navigation system on 25 June.

The 17 August Q2 print is the first quarter with HOPE clinic operations in swing under the Zeta workflow; the setup is whether the operating-clinic story shows revenue traction or the Kadima dispute drags on the transition — the 2027 EPS step depends on the former.

Agrees with X sentimentX frames it as a digital-mental-health inflection with the Emobot EMOCARE Depression Thermometer validation at ASCP 2026 and a 45% one-month rally. That matches the HOPE-clinic first-patient news and the analyst step-change to 2027, though the crowd underplays the Kadima dispute as a variable.

What to watch: The 17 August Q2 print — HOPE Therapeutics clinic revenue traction, patient count, cash runway, and any Kadima-litigation updates. NRX-101 expanded-access protocol data also would be scientific-catalyst reads.

On the calendar: Q2 earnings 17 August 2026

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-06-04

NRx Pharmaceuticals' strategic partner Emobot presented late-breaking clinical validation of the EMOCARE Depression Thermometer at ASCP 2026, with pooled analysis showing 90 percent within-person concordance with clinician MADRS (r=0.895, p=0.016) for passive smartphone-based depression monitoring. The stock is up roughly 45 percent over the past month and was named among Best Rated Penny Stocks by Wall Street analysts. Tone is bullish on the digital-mental-health validation.

Read the AI verdict + X sentiment for $NRXP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops Zyesami (aviptadil) for respiratory distress and NRX-101 for bipolar disorder; small clinical-stage specialty pharma.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NRXP.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NRXP

Neutral — Develops Zyesami (aviptadil) for respiratory distress and NRX-101 for bipolar disorder; small clinical-stage specialty pharma; end markets and revenue mix have limited overlap with the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
133%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-7.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-20.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
31.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
108%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
37.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 15, 2026$-0.04$-0.05+20.0%
Q4 2025Mar 23, 2026$0.19$-0.09+311.1%
Q3 2025Nov 14, 2025$-0.18$-0.11-63.6%
Q1 2025May 15, 2025$-0.34$-0.30-13.3%
Next earningsMon, Aug 17·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.1M—25.5%-445%$-0.04$-4.3M
Q4 FY25$983K—48.3%-467%$0.01$-3.7M
Q3 FY25$242K—43.0%-1702%$-0.27$-2.9M
Q2 FY25$0———$-0.98$-4.0M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.9M$12.9M – $14.9M-$0.37-$0.45 – -$0.292
FY27$165.6M$68.3M – $262.9M$0.35$0.30 – $0.403
FY28$498.8M$155.9M – $1.0B$2.49$0.26 – $5.761
FY29$745.1M$232.9M – $1.5B$4.51$0.48 – $10.431
FY30$935.1M$292.2M – $1.9B$5.76$0.61 – $13.321

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.76%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+53.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 14.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.195-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 award) in window

See when $NRXP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 48-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

NRXP (NRXP) disclosed entry into a material definitive agreement under 8-K Item 1.01. The agreement involves consideration of approximately $18.8 million. Material agreements require 8-K disclosure within four business days of execution as they may significantly affect the company's business, financial condition, or operations. The full terms and conditions of the agreement are typically attached as an exhibit to the 8-K filing.

424B5Prospectus supplement (offering)Jun 3424B5
AI summary

Common Stock NRx Pharmaceuticals, Inc. (NRXP) filed a 424B5 prospectus supplement for a securities offering. The offering involves securities valued at approximately $0. The 424B5 is filed under an effective shelf registration, enabling rapid capital markets execution. Proceeds are expected to be used for general corporate purposes including potential acquisitions, debt reduction, or operational funding.

424B5Prospectus supplement (offering)Jun 2424B5
AI summary

NRx Pharmaceuticals filed a 424B5 prospectus supplement for an underwritten common stock offering; the excerpt shows only the table of contents with no deal size or pricing visible. Body unavailable — only table of contents in excerpt.

8-KOfficer or director changeMar 248-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
3New insider — initial holdingsFeb 173
424B5Prospectus supplement (offering)Feb 17424B5
8-KOfficer or director changeFeb 28-K — Item 5.02: Officer or director change
+ 11 other (3 routine 8-Ks · 2 proxys · 1 25-NSE · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Disputeglobenewswire.com·21d agoNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation Systemglobenewswire.com·22d agoKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisitionbusinesswire.com·23d agoZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeuticsprnewswire.com·24d agoNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depressionglobenewswire.com·25d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · last 7 days

No standout posts about $NRXP on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport